RAPT Therapeutics (RAPT) Return on Equity (2020 - 2024)
Historic Return on Equity for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to 0.32%.
- Therapeutics' Return on Equity rose 3100.0% to 0.32% in Q3 2024 from the same period last year, while for Sep 2024 it was 0.32%, marking a year-over-year increase of 3100.0%. This contributed to the annual value of 0.65% for FY2023, which is 2500.0% down from last year.
- As of Q3 2024, Therapeutics' Return on Equity stood at 0.32%, which was up 3100.0% from 0.56% recorded in Q2 2024.
- In the past 5 years, Therapeutics' Return on Equity ranged from a high of 0.31% in Q3 2021 and a low of 0.79% during Q4 2023
- Moreover, its 5-year median value for Return on Equity was 0.41% (2022), whereas its average is 0.48%.
- As far as peak fluctuations go, Therapeutics' Return on Equity tumbled by -4000bps in 2023, and later skyrocketed by 3100bps in 2024.
- Quarter analysis of 5 years shows Therapeutics' Return on Equity stood at 0.49% in 2020, then grew by 28bps to 0.36% in 2021, then decreased by -11bps to 0.39% in 2022, then tumbled by -101bps to 0.79% in 2023, then skyrocketed by 59bps to 0.32% in 2024.
- Its last three reported values are 0.32% in Q3 2024, 0.56% for Q2 2024, and 0.69% during Q1 2024.